Usynova

News

AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese biotech Usynova for $24 million upfront.

News

Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.